AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23091109
Drug: Bortezomib 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.3 mg/m², thalidomide 100 mg, and dexamethasone 40 mg with cyclophosphamide 400 mg/m² (VTDC)
Trial: 21723605
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of donepezil (10 mg)
Trial: 21723605
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of donepezil (10 mg)
Trial: 12653691
Drug: Caffeine-replete (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine-replete (200 mg caffeine capsules twice daily)
Trial: 11885175
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed in augmented maxillary sinuses using various grafting materials (autogenous bone, DFDBA, HA, combination grafts)
Trial: 11885175
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed in the posterior maxilla without sinus grafting
Trial: 11885175
Drug: Overall implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall implants placed
Trial: 8807564
Drug: Mineral tablets
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineral tablets containing calcium, potassium and sodium phosphates (Redusan Combi) during first 4 weeks
Trial: 8807564
Drug: Placebo first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo first and mineral tablets in the final period (group 2)
Trial: 1570233
Drug: Experimental buccal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental buccal formulation of piroxicam (20 mg daily)
Trial: 1570233
Drug: Oral capsules
RxNorm normalized name: Plenity Oral Capsules
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral capsules of piroxicam (20 mg daily)
Trial: 6367129
Drug: Saline (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (same volume as cefuroxime, administered by the same route)
Trial: 6367129
Drug: Antibiotic treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic treated group (cefuroxime)
Trial: 24517291
Drug: Low-dose NCCT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose NCCT (5, 7.5, 15, 30, 50, 70, and 140 mAs)
Trial: 24517291
Drug: Conventional-dose NCCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose NCCT (not explicitly defined in terms of mAs)
Trial: 9513626
Drug: Take-home medication
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Take-home medication
Trial: 12450962
Drug: Dose increase
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose increase
Trial: 9513626
Drug: Additional service
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional service items (e.g., rent, food or gas payments; employment assistance; medical care)
Trial: 8061173
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate (120 mg q.i.d.) and amoxycillin (500 mg q.i.d.)
Trial: 3288467
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release nifedipine 20mg twice daily
Trial: 31269364
Drug: Rituximab (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (two infusions, 1000 mg each, administered 14 days apart; repeated at 6 months in case of partial response)
Trial: 31269364
Drug: Cyclosporine (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (starting at a dose of 3.5 mg per kilogram of body weight per day for 12 months)
Trial: 24555233
Drug: Bolus intravenous
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus intravenous administration of cytoflavin
Trial: 24555233
Drug: Dropwise intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dropwise intravenous injection of cytoflavin
Trial: 21240870
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate 30 mg daily, titrated to a maximum dosage of 120 mg daily for 24 weeks.
Trial: 18048424
Drug: Creatine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (2 g/day)
Trial: 16982453
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous immunoglobulin (IVIG) at a daily dose of 400 mg/kg for 2-3 times
Trial: 11022778
Drug: SDD 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDD 10 mg qd
Trial: 11022778
Drug: SDD 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDD 20 mg qd
Trial: 11022778
Drug: SDD 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDD 20 mg bid
Trial: 7525886
Drug: Cisplatin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (100 mg/m2 during every other cycle) with 5-FU (800 mg/m2/d) and HU (escalating doses) and concomitant radiotherapy (1.8 to 2.0 Gy on days 1 to 5) plus G-CSF (5 micrograms/kg/d on days 6 to 13)
Trial: 7525886
Drug: 5-FU (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU (800 mg/m2/d) and HU (escalating doses) and concomitant radiotherapy (1.8 to 2.0 Gy on days 1 to 5) without G-CSF
Trial: 19302707
Drug: IFN beta‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN beta‐1a 44 mcg biw
Trial: 19302707
Drug: IFN beta‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN beta‐1a 44 mcg tiw
Trial: 19302707
Drug: IFN beta‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN beta‐1a 66 mcg tiw
Trial: 7695422
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (16 mmol continuously from anesthetic induction to aortic cross‐clamping, followed by 32 mmol starting after release of aortic cross‐clamp until 24 hours later)
Trial: 7695422
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (Group A)
Trial: 1015538
Drug: Postoperative systemic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative systemic BCG adjuvant immunotherapy
Trial: 27808588
Drug: Myo-inositol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myo-inositol (4 g/day)
Trial: 12091045
Drug: 3.500 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.500 IU anti‐Xa of tinzaparin (Innohep) subcutaneously once daily
Trial: 2403851
Drug: 0 ml.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 ml.kg‐1 apple juice
Trial: 2403851
Drug: 6 ml.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 ml.kg‐1 apple juice
Trial: 2403851
Drug: 10 ml.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml.kg‐1 apple juice
Trial: 341903
Drug: Halopredone acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halopredone acetate (0.05% in cream)
Trial: 341903
Drug: Fluocinonide (0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluocinonide (0.05% in cream)
Trial: 19356750
Drug: Needle-free CO(2)
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle-free CO(2) injection system (Biojector 2000)
Trial: 19356750
Drug: Traditional sharp
RxNorm normalized name: shark preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional sharp needles for gonadotropin injections
Trial: 12471719
Drug: Test group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test group (vegetable drink with 0.5 g of sardine peptides and 0.4 mg of VY)
Trial: 12471719
Drug: Excessive ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excessive ingestion test (585 g of test drink for 14 days)
Trial: 12471719
Drug: Excessive ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excessive ingestion test (585 g of control drink for 14 days)
Trial: 8573948
Drug: 2-hour amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-hour amphotericin B infusions
Trial: 8573948
Drug: 4-hour amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-hour amphotericin B infusions
Trial: 8573948
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment regimens
Trial: 29150536
Drug: Treatment regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment regimens
Trial: 2617169
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg o.m. + Amoxicillin 750 mg b.i.d (Group 1)
Trial: 2617169
Drug: Amoxicillin 750
RxNorm normalized name: amoxicillin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 750 mg b.i.d (Group 3)
Trial: 2617169
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg o.m. (Group 2)
Trial: 321487
Drug: Indoprofen (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoprofen (three dose levels)
Trial: 321487
Drug: ASA (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA (three dose levels)
Trial: 27105332
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of omega‐3 and PEP
Trial: 29625834
Drug: Guided Internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided Internet-based cognitive behavioral treatment (ICBT) for 12 weeks
Trial: 29625834
Drug: Unguided Internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unguided Internet-based cognitive behavioral treatment (ICBT) for 12 weeks
Trial: 24609919
Drug: 12 month
RxNorm normalized name: Elecare HMO 0-12 Months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 month intervention group (three face to face visits with a lifestyle counsellor plus monthly 15 minute telephone calls)
Trial: 19369056
Drug: EGG group
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGG group (640 mg additional cholesterol)
Trial: 11880821
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (0.3 g x kg(‐1) x d(‐1) for 7 days)
Trial: 10511768
Drug: Captopril (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (0.7 mg/kg)
Trial: 10511768
Drug: Captopril (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (0.7 mg/kg) and Furosemide (1 mg/kg)
Trial: 26932302
Drug: Empagliflozin 12.5
RxNorm normalized name: empagliflozin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 12.5 mg/metformin 1,000 mg FDC
Trial: 26932302
Drug: Individual tablets
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual tablets of empagliflozin and metformin
Trial: 18434221
Drug: Active physical
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active physical treatment (APT) - 10 weeks of aerobic training and muscle strengthening of back extensors
Trial: 18434221
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (CT) - APT combined with GAP
Trial: 16306196
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with indomethacin (0.1 mg/kg/24 h for three doses) and L‐NMMA (infusion for 72 hours)
Trial: 16306196
Drug: Indomethacin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.1 mg/kg/24 h for three doses)
Trial: 10099034
Drug: Nicardipine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (60 or 90 mg/d)
Trial: 6232263
Drug: Nomifensine maleate
RxNorm normalized name: nomifensine maleate
DrugBank: Nomifensine (DB04821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nomifensine maleate (100-200 mg/day)
Trial: 31421635
Drug: D-cycloserine (DCS)
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-cycloserine (DCS) treatment (250 mg for 2 days, 500 mg for 2 days, 750 mg for 3 days, and 1000 mg for 5 weeks)
Trial: 29247343
Drug: Caffeine-maltodextrin mouth
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine-maltodextrin mouth rinse (MR: 0.3 g/25 ml CAF: 1.6g/25 ml MALT)
Trial: 29247343
Drug: Placebo (PLAC:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLAC: 25 ml artificial saliva)
Trial: 27965251
Drug: AKUD trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKUD trial (app‐administered self‐care acupressure)
Trial: 23886416
Drug: 4.3 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.3 Gy × 10 fractions (target dose 43 Gy)
Trial: 23886416
Drug: 2.5 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 Gy × 20 fractions (target dose 50 Gy)
Trial: 17694310
Drug: Gefitinib 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 1000 mg/day with temozolomide for patients on EIAEDs
Trial: 17694310
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg/day with temozolomide for patients not on EIAEDs
Trial: 17694310
Drug: Gefitinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib and temozolomide combination
Trial: 17019957
Drug: Low‐intensive laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐intensive laser radiation (LILR) monotherapy
Trial: 17019957
Drug: Low‐intensive laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐intensive laser radiation (LILR) plus conventional drug therapy (CDT)
Trial: 17019957
Drug: Conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug therapy (CDT) only
Trial: 10780761
Drug: zafirlukast 80
RxNorm normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: zafirlukast 80 mg
Trial: 10780761
Drug: zafirlukast 20
RxNorm normalized name: zafirlukast 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zafirlukast 20 mg
Trial: 25291130
Drug: Active formulation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active formulation containing 250 mg of tara gum and 1 billion viable cells of S. thermophilus ST10
Trial: 22837118
Drug: Meperedine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperedine (0.4 mg/Kg/IV)
Trial: 22837118
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg/IV)
Trial: 18038601
Drug: N-acetylcysteine in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine in complex therapy
Trial: 16129716
Drug: High-calcium diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-calcium diet (1400 mg of calcium)
Trial: 16129716
Drug: Moderate-calcium diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-calcium diet (800 mg of calcium)
Trial: 16129716
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (standard diet with 800 mg of calcium)
Trial: 11872102
Drug: 2 mL/hour
RxNorm normalized name: bupivacaine HCl/PF 0.5 % 2 mL/hour 100 mL INJECTION ELASTOMERIC PUMP, FIXED RATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL/hour
Trial: 11872102
Drug: 20 mL/hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL/hour
Trial: 11872102
Drug: 50 mL/hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mL/hour
Trial: 11872102
Drug: 100 mL/hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL/hour
Trial: 11872102
Drug: All administration
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All administration sets
Trial: 3416310
Drug: 10-ethyl-10-deazaaminopterin (10-EDAM)
RxNorm normalized name: ethyl 10-undecenoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-ethyl-10-deazaaminopterin (10-EDAM) i.v. at dosage levels ranging from 5 to 120 mg/m2
Trial: 3416310
Drug: 10-EDAM i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-EDAM i.v. weekly x 3 schedule (35 patients) or weekly schedule (27 patients)
Trial: 3416310
Drug: 10-EDAM i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-EDAM i.v. weekly at 80 mg/m2 or 100 mg/m2 weekly for 3 weeks
Trial: 3416310
Drug: Pharmacokinetic studies
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacokinetic studies at 5, 30, and 100 mg/m2 dosage levels
Trial: 19816648
Drug: Monthly ibandronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly ibandronate 150 mg for 3 months
Trial: 19816648
Drug: Weekly risedronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly risedronate 35 mg for 12 weeks
Trial: 16831952
Drug: Monthly ibandronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly ibandronate
Trial: 19816648
Drug: Weekly risedronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly risedronate
Trial: 11575038
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received conventional therapy (antidepressant paroxetine plus weekly psychotherapy for 8 weeks)
Trial: 5309529
Drug: Intradermal jet
RxNorm normalized name: Jet Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal jet injection using diluted smallpox vaccine with a titre of 10(6.3) TCID(50)/ml
Trial: 5309529
Drug: Intradermal jet
RxNorm normalized name: Jet Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal jet injection using diluted smallpox vaccine with a titre of 10(7.0) TCID(50)/ml
Trial: 5309529
Drug: Multiple-pressure vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-pressure vaccination using undiluted vaccine
Trial: 5309529
Drug: Intradermal jet
RxNorm normalized name: Jet Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal jet injection using diluted smallpox vaccine with a titre of 10(6.0) TCID(50)/ml
Trial: 5309529
Drug: Intradermal jet
RxNorm normalized name: Jet Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal jet injection using diluted smallpox vaccine with a titre of 10(5.0) TCID(50)/ml
Trial: 31292007
Drug: Intracavitary steroids
RxNorm normalized name: carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracavitary steroids (80 mg of methylprednisolone)
Trial: 21811797
Drug: tramadol/APAP (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tramadol/APAP (37.5 mg/325 mg)
Trial: 21811797
Drug: tramadol/APAP and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tramadol/APAP and NSAID combination therapy
Trial: 17314577
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg M6G
Trial: 11453311
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg moxifloxacin once daily for 10 days
Trial: 11453311
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg moxifloxacin once daily for 10 days
Trial: 8092599
Drug: 0 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mL/kg magnesium citrate
Trial: 8092599
Drug: 4 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL/kg magnesium citrate
Trial: 8092599
Drug: 6 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mL/kg magnesium citrate
Trial: 8092599
Drug: 8 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mL/kg magnesium citrate
Trial: 21309709
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg/day
Trial: 3337929
Drug: Naproxen 1500
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 1500 mg/day
Trial: 29150968
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no light administered)
Trial: 24127200
Drug: Naproxen submicron
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen submicron particle capsules 200 mg
Trial: 24127200
Drug: Naproxen tablets
RxNorm normalized name: Naproxen Tablets
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen tablets 250 mg
Trial: 24127200
Drug: Naproxen submicron
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen submicron particle capsules 400 mg
Trial: 24127200
Drug: Naproxen tablets
RxNorm normalized name: Naproxen Tablets
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen tablets 500 mg
Trial: 16538941
Drug: Mitigator Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitigator Sting and Bite Treatment